American Institute for Cancer Research

Financial Report
September 30, 2022

Contents

Independent Auditor's Report

Board of Directors
American Institute for Cancer Research

Opinion
We have audited the financial statements of American Institute for Cancer Research (the Institute), which comprise the statements of financial position as of September 30, 2022 and 2021, the related statements of activities, functional expenses and cash flows for the years then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Institute as of September 30, 2022 and 2021, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion
We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Institute and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements
Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America and for the design, implementation and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Institute's ability to continue as a going concern within one year after the date that the financial statements are issued or available to be issued.

Auditor's Responsibilities for the Audit of the Financial Statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and, therefore, is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Institute's internal control. Accordingly, no such opinion is expressed.

- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.

- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Institute's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

RSM US LLP

McLean, Virginia
March 15, 2023

American Institute for Cancer Research

Statements of Financial Position
September 30, 2022 and 2021

	2022	2021
Assets		
Cash and cash equivalents (Note 1)	$ 5,958,891	$ 6,418,874
Accounts receivable, net of allowance for uncollectible accounts of $4,364 in 2022 and $4,175 in 2021	97,957	126,128
Due from affiliates (Note 12)	937,400	453,888
Bequests receivable (Note 4)	1,860,511	1,636,079
Investments (Notes 2 and 3)	6,828,067	8,128,236
Prepaid expenses and other assets	613,345	618,106
Property and equipment, net (Note 5)	310,910	428,289
Beneficial interest in perpetual trust (Notes 2 and 3)	308,626	404,897
Total assets	$ 16,915,707	$ 18,214,497
Liabilities and Net Assets		
Liabilities:		
Accounts payable and accrued expenses	$ 476,349	$ 572,269
Due to affiliates (Note 12)	-	258,848
Grants payable (Note 6)	2,179,249	2,061,301
Deferred rent	919,689	1,030,170
Liabilities under charitable gift annuities (Notes 2 and 3)	851,051	986,920
Liabilities under charitable remainder unitrusts (Notes 2 and 3)	354,387	505,346
Accrued benefit cost (Note 11)	-	-
Total liabilities	4,780,725	5,414,854
Commitments (Notes 3 and 14)		
Net assets:		
Without donor restrictions (Note 7)	5,674,642	8,018,204
With donor restrictions (Notes 8 and 9)	6,460,340	4,781,439
Total net assets	12,134,982	12,799,643
Total liabilities and net assets	$ 16,915,707	$ 18,214,497

See notes to financial statements.

American Institute for Cancer Research

Statement of Activities
Year Ended September 30, 2022

	Without Donor Restrictions	With Donor Restrictions	Total
Support and revenues:			
Public support—contributions and bequests	$ 7,987,600	$ 4,286,335	$ 12,273,935
Program service revenue	84,850	-	84,850
Affiliate service fees	1,559,280	-	1,559,280
List rental income	167,003	-	167,003
Interest income and dividends (Note 2), net of fees	155,864	41,627	197,491
Other revenue	32,539	-	32,539
Net assets released from restrictions	1,926,080	(1,926,080)	-
Total support and revenues	11,913,216	2,401,882	14,315,098
Expenses (Note 13):			
Program services:			
Research	2,173,462	-	2,173,462
Public health education	6,876,430	-	6,876,430
Total program services	9,049,892	-	9,049,892
Supporting services:			
Management and general	1,698,941	-	1,698,941
Fundraising	2,899,233	-	2,899,233
Total supporting services	4,598,174	-	4,598,174
Total expenses	13,648,066	-	13,648,066
Change in net assets before other changes	(1,734,850)	2,401,882	667,032
Other changes:			
Other gains:			
Net realized and unrealized loss on investments	(775,434)	(485,136)	(1,260,570)
Change in value of split-interest agreement liability—annuities	166,722	-	166,722
Change in value of split-interest agreement liability—trusts		(141,574)	(141,574)
Net loss on interest in perpetual trust (Note 2)	-	(96,271)	(96,271)
Change in net assets	(2,343,562)	1,678,901	(664,661)
Net assets:			
Beginning	8,018,204	4,781,439	12,799,643
Ending	$ 5,674,642	$ 6,460,340	$ 12,134,982

See notes to financial statements.

American Institute for Cancer Research

Statement of Activities
Year Ended September 30, 2021

	Without Donor Restrictions	With Donor Restrictions	Total
Support and revenues:			
Public support—contributions and bequests	$ 9,311,167	$ 1,526,640	$ 10,837,807
Program service revenue	22,624	-	22,624
Affiliate service fees	1,030,788	-	1,030,788
List rental income	205,181	-	205,181
Interest income and dividends (Note 2), net of fees	155,428	52,670	208,098
Other revenue	1,284,191	-	1,284,191
Net assets released from restrictions	1,428,505	(1,428,505)	-
Total support and revenues	13,437,884	150,805	13,588,689
Expenses (Note 13):			
Program services:			
Research	2,127,010	-	2,127,010
Public health education	7,040,638	-	7,040,638
Total program services	9,167,648	-	9,167,648
Supporting services:			
Management and general	2,131,481	-	2,131,481
Fundraising	2,901,995	-	2,901,995
Total supporting services	5,033,476	-	5,033,476
Total expenses	14,201,124	-	14,201,124
Change in net assets before other changes	(763,240)	150,805	(612,435)
Other changes:			
Other gains:			
Net realized and unrealized gain on investments	700,031	234,418	934,449
Change in value of split-interest agreement liability—annuities	306,423	-	306,423
Change in value of split-interest agreement liability—trusts	-	43,080	43,080
Net gain on interest in perpetual trust (Note 2)	-	35,849	35,849
Change in net assets	243,214	464,152	707,366
Net assets:			
Beginning	7,774,990	4,317,287	12,092,277
Ending	$ 8,018,204	$ 4,781,439	$ 12,799,643

See notes to financial statements.

American Institute for Cancer Research

Statement of Functional Expenses
Year Ended September 30, 2022

	Program Services			Supporting Services			
	Research	Public Health Education	Total Program Services	Management and General	Fundraising	Total Supporting Services	Totals
Grants	$ 1,319,270	$ 256,142	$ 1,575,412	$ -	$ -	$ -	$ 1,575,412
Postage and delivery	621	1,612,053	1,612,674	38,241	798,286	836,527	2,449,201
Printing and publication	1,810	1,256,230	1,258,040	39,389	500,095	539,484	1,797,524
Data processing	2,738	468,426	471,164	79,303	260,579	339,882	811,046
Mailhouse fees	-	455,403	455,403	14,316	259,026	273,342	728,745
List costs	-	257,045	257,045	-	176,226	176,226	433,271
Salaries and director fees	472,935	1,174,007	1,646,942	882,018	401,939	1,283,957	2,930,899
Professional fees	70,043	595,939	665,982	141,830	261,235	403,065	1,069,047
Occupancy	37,119	129,918	167,037	98,985	43,307	142,292	309,329
Travel and entertainment	20,447	7,143	27,590	2,458	616	3,074	30,664
Benefits and payroll taxes	66,715	200,747	267,462	149,066	66,807	215,873	483,335
Office expense	16,905	81,845	98,750	53,027	38,532	91,559	190,309
Depreciation and amortization	14,086	49,299	63,385	37,561	16,433	53,994	117,379
Insurance	3,554	12,440	15,994	9,478	4,146	13,624	29,618
Advertising	-	3,412	3,412	6,009	3,065	9,074	12,486
Information technology	122,636	88,280	210,916	47,663	31,505	79,168	290,084
Conferences	1,508	8,124	9,632	226	526	752	10,384
Interest expense	-	-	-	35,675	-	35,675	35,675
WCRF membership dues	-	69,219	69,219	-	-	-	69,219
Miscellaneous	23,075	150,758	173,833	63,696	36,910	100,606	274,439
	$ 2,173,462	$ 6,876,430	$ 9,049,892	$ 1,698,941	$ 2,899,233	$ 4,598,174	$ 13,648,066

See notes to financial statements.

American Institute for Cancer Research

Statement of Functional Expenses
Year Ended September 30, 2021

	Program Services			Supporting Services			
	Research	Public Health Education	Total Program Services	Management and General	Fundraising	Total Supporting Services	Totals
Grants	$ 1,270,271	$ 296,579	$ 1,566,850	$ -	$ -	$ -	$ 1,566,850
Postage and delivery	2,125	1,632,494	1,634,619	63,310	823,604	886,914	2,521,533
Printing and publication	1,610	1,076,515	1,078,125	73,904	402,761	476,665	1,554,790
Data processing	29,837	456,372	486,209	135,831	243,403	379,234	865,443
Mailhouse fees	-	457,155	457,155	15,962	255,294	271,256	728,411
List costs	-	165,508	165,508	-	113,983	113,983	279,491
Salaries and director fees	399,515	1,499,121	1,898,636	1,050,328	426,227	1,476,555	3,375,191
Professional fees	77,788	693,919	771,707	182,129	342,796	524,925	1,296,632
Occupancy	46,952	118,945	165,897	100,165	46,953	147,118	313,015
Travel and entertainment	7,578	1,669	9,247	956	599	1,555	10,802
Benefits and payroll taxes	87,843	249,574	337,417	225,139	101,778	326,917	664,334
Pension expense (Note 11)	9,808	36,308	46,116	55,690	10,793	66,483	112,599
Office expense	23,520	70,525	94,045	58,633	40,155	98,788	192,833
Depreciation and amortization	18,231	46,185	64,416	38,892	18,231	57,123	121,539
Insurance	3,438	8,710	12,148	7,335	3,438	10,773	22,921
Advertising	-	12,881	12,881	9,686	30,266	39,952	52,833
Information technology	114,636	76,747	191,383	34,046	26,937	60,983	252,366
Conferences	703	3,013	3,716	79	185	264	3,980
Interest expense	-	-	-	52,729	-	52,729	52,729
WCRF membership dues	-	65,940	65,940	-	-	-	65,940
Miscellaneous	33,155	72,478	105,633	26,667	14,592	41,259	146,892
	$ 2,127,010	$ 7,040,638	$ 9,167,648	$ 2,131,481	$ 2,901,995	$ 5,033,476	$ 14,201,124

See notes to financial statements.

American Institute for Cancer Research

Statements of Cash Flows
Years Ended September 30, 2022 and 2021

	2022	2021
Cash flows from operating activities:		
Change in net assets	**$ (664,661)**	$ 707,366
Adjustments to reconcile change in net assets to net cash used in operating activities:		
Depreciation and amortization	**117,379**	121,539
Net realized and unrealized loss (gain) on investments	**1,260,570**	(934,449)
Contributions from stock gifts	**(991)**	(9,185)
Net loss (gain) on investments held for split-interest agreements	**290,704**	(37,729)
Net loss (gain) on beneficial interest in perpetual trust	**96,271**	(35,849)
Loss on sale of furniture, equipment and leasehold improvements	**-**	103
Forgiveness of debt	**-**	(1,323,455)
Contributions received for long-term purposes	**(290,307)**	(221,500)
Deferred rent	**(110,481)**	(99,491)
(Increase) decrease in assets:		
Accounts receivable	**28,171**	68,426
Due from affiliates	**(483,512)**	191,630
Bequests receivable	**(224,432)**	46,790
Prepaid expenses	**4,761**	(250,034)
Increase (decrease) in liabilities:		
Accounts payable and accrued expenses	**(95,920)**	(239,706)
Due to affiliates	**(258,848)**	(547,940)
Grants payable	**117,948**	(264,825)
Liabilities under charitable gift annuity agreements	**(135,869)**	(325,437)
Liabilities under charitable remainder unitrust agreements	**(150,959)**	(2,555)
Accrued benefit cost	**-**	(1,365,728)
Net cash used in operating activities	**(500,176)**	(4,522,029)
Cash flows from investing activities:		
Acquisition of furniture, equipment and leasehold improvements	**-**	(21,785)
Purchase of investments	**(912,737)**	(1,364,036)
Proceeds from maturities and sales of investments	**662,623**	1,694,698
Net cash (used in) provided by investing activities	**(250,114)**	308,877
Cash flows from financing activities:		
Proceeds from note payable	**-**	675,855
Contributions received for long-term purposes	**290,307**	221,500
Net cash provided by financing activities	**290,307**	897,355
Net decrease in cash and cash equivalents	**(459,983)**	(3,315,797)
Cash and cash equivalents:		
Beginning	**6,418,874**	9,734,671
Ending	**$ 5,958,891**	$ 6,418,874
Supplemental schedule of noncash financing activities:		
Reduction of notes payable via forgiveness	**$ -**	$ 1,323,455

See notes to financial statements.

Note 1. Nature of Activities and Significant Accounting Policies

Nature of activities: American Institute for Cancer Research (the Institute) was incorporated in the District of Columbia in September 1981. The primary objectives of the Institute are to promote, expand and encourage public knowledge on how the risk of cancer is reduced by healthy food and nutrition, physical activity and weight management, the causes and treatment of cancer in general, and to fund, support and encourage innovative scientific research as to the causes, prevention and treatment of cancer.

A summary of the Institute's significant accounting policies follows:

Basis of presentation: The financial statement presentation follows the recommendations of the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC). As required by the Not-for-Profit Topic of the FASB ASC, Financial Statements of Not-for-Profit Organizations, the Institute is required to report information regarding its financial position and activities according to two classes of net assets: net assets without donor restrictions and net assets with donor restrictions.

Net assets without donor restrictions: Net assets not subject to donor-imposed stipulations.

Net assets with donor restrictions: Net assets subject to donor-imposed stipulations that may or will be met either by actions of the Institute and/or the passage of time. Net assets with donor restrictions also includes net assets subject to donor-imposed stipulations that the assets will be maintained permanently by the Institute.

Revenues are reported as increases in net assets without donor restrictions unless use of the related assets is limited by donor-imposed restrictions. Expenses are reported as decreases in net assets without donor restrictions. Gains and losses on investments and other assets or liabilities are reported as increases or decreases in net assets without donor restrictions unless their use is restricted by explicit donor stipulation or by law.

Expirations of restrictions on net assets (i.e., the donor-stipulated purpose has been fulfilled and/or the stipulated time period has elapsed) and changes in donor intent are reported as reclassifications between the applicable classes of net assets.

Cash and cash equivalents: The Institute maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. The Institute has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on its cash balances.

Cash equivalents include items that are readily convertible into cash and are stated at cost, which approximates fair value. Cash equivalents of $963,269 and $881,447 at September 30, 2022 and 2021, respectively, consisted of money market accounts and overnight deposits.

Receivables: Accounts receivable are recorded at the invoiced amount and bequests receivable are recorded at the amount promised to the Institute.

The Institute maintains an allowance for uncollectable accounts for estimated losses inherent in its receivable portfolio. In establishing the required allowance, management considers historical losses and current receivable aging and current payment patterns. Account balances are charged off against the allowance when the potential for recovery is considered remote.

Note 1. Nature of Activities and Significant Accounting Policies (Continued)

Investments: Investments consist of U.S. government and government agency securities, corporate bonds, fixed income and equity mutual funds, common trust funds and stocks with readily determinable fair values and are reflected at fair value. Investments are exposed to certain risks, such as interest rate, credit and overall market volatility. Due to the level of risk associated with certain investment securities and the volatility of capital markets, changes in the value of investment securities could occur in the near-term, and these changes could materially differ from the amounts reported in the accompanying financial statements.

Prepaid expenses: Prepaid expenses consist primarily of prepaid postage, prepaid rent and security deposits.

Property and equipment, net: Expenditures for furniture and fixtures, equipment and leasehold improvements are capitalized at cost. The Institute capitalizes all property and equipment purchased with a cost of $500 or more. Furniture and fixtures and equipment are depreciated on the straight-line basis over estimated useful lives of three to five years. Leasehold improvements are amortized on a straight-line basis over the shorter of the asset life or the remaining term of the lease. Donated land is reported at fair value as of the date of donation.

Valuation of long-lived assets: The Institute reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets. Assets to be disposed of are reported at the lower of the carrying value or fair value, less costs to sell.

Grants payable: The Institute recognizes grant expense and the related liability in the year an unconditional grant is awarded.

Deferred rent: The Institute has entered into an operating lease agreement, which contains provisions for future rent increases and periods of free or reduced rent. In accordance with generally accepted accounting principles in the United States of America (U.S. GAAP), the Institute records monthly rent expense equal to the total of the payments due over the lease term, divided by the number of months of the lease term. The difference between rent expense recorded and the amount paid is charged to deferred rent, which is reflected as a separate line item in the accompanying balance sheet. The operating lease agreement also includes a tenant improvement allowance. The tenant improvement allowance is recorded as a deferred lease incentive and included within the deferred rent liability in the accompanying balance sheet. The deferred lease incentive is amortized as a credit to rent expense over the term of the lease.

Revenue recognition: Public support is recorded as support and revenue when unconditional contributions, which include unconditional promises to give (pledges), are received. Restricted contributions are reported as increases in net assets with donor restrictions and are reclassified to net assets without donor restrictions when restrictions are met. Restricted contributions, which have restrictions that are satisfied in the year received, are reported as increases in net assets without donor restrictions.

Contributions due in future periods are considered as net assets with donor restrictions until the period in which they are due, at which time the restriction is released. Contributions of property and equipment are recognized at fair value at the date of contribution.

Note 1. Nature of Activities and Significant Accounting Policies (Continued)

Bequests are recognized as public support revenues when the underlying will is declared valid by the respective probate court.

The Institute's revenue streams under contracts with customers are comprised of affiliate service fees, program service revenue and mailing list rental revenues. The Institute's revenue is recognized when a given performance obligation is satisfied, either over a period of time or at a point in time. The majority of the Institute's revenue under contracts from customers is earned in the United States.

Affiliate service fees represent reimbursement for services provided by the Institute to international affiliates (see Note 12) and are recognized as earned.

Program service revenue consists of income from the sale of books and bulk publications, which is recognized at the time of sale and conference revenue which is recognized upon completion of conference events.

Other revenue consists primarily of mailing list rental revenues, which are recognized at the time of broker distribution of lists to the interested parties.

All of the Institute's revenue from contracts with customers are derived from contracts with an initial duration of one year or less. Prices are specific to a distinct performance obligation and do not consist of multiple transactions. There were no changes in affiliate service fees, program service revenue and mailing list rental revenue that would affect the economic seasonality of the statements of financial position. The Institute did not have any impairment or credit losses on any receivables arising from contracts with customers. There are also no incremental costs of obtaining a contract and no significant financing components. Finally, there are no significant changes in the judgements affecting the determination of the amount and timing of revenue from contracts with customers.

Functional allocation of expenses: The costs of providing programs and services are summarized on a functional basis in the accompanying financial statements. Accordingly, certain costs have been allocated among the programs and supporting services benefited. Joint costs of informational materials or activities that included a fundraising appeal have been allocated among fundraising and the appropriate program or management and general functions.

For the year ended September 30, 2022, the Institute's expenses totaled $13,648,066. Of that amount, 16% was spent directly in support of cancer research and 50% of expenses went in support of the Institute's public education programs in cancer prevention. Together, research and public education programs account for 66% of all expenditures by the Institute. Fundraising costs for the year were 21% of total expenses and 13% of expenses went to administrative costs.

For the year ended September 30, 2021, the Institute's expenses totaled $14,201,124. Of that amount, 15% was spent directly in support of cancer research and 50% of expenses went in support of the Institute's public education programs in cancer prevention. Together, research and public education programs account for 65% of all expenditures by the Institute. Fundraising costs for the year were 20% of total expenses and 15% of expenses went to administrative costs.

Use of estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Note 1. Nature of Activities and Significant Accounting Policies (Continued)

Recent accounting pronouncement: In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02: *Leases (Topic 842)*, an amendment to the FASB ASC. Under ASU 2016-02, lessees will recognize most leases on their statement of financial position as a right-of-use asset and a lease liability for all future lease payments. During November 2019, the FASB issued ASU 2019-10, *Leases (Topic 842) Effective Dates*, which delayed the effective date of ASU 2016-02 by one year. In June 2020, the FASB issued ASU 2020-05, *Revenue from Contracts with Customers (Topic 606) and Leases (Topic 842): Effective Dates for Certain Entities,* further delaying the effective date an additional year, making it effective for annual reporting periods beginning after December 15, 2021. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Institute has not elected to early adopt the guidance and is currently evaluating the impact on financial statements and related disclosures.

Subsequent events: The Institute has evaluated subsequent events through March 15, 2023, the date on which the financial statements were available to be issued.

Note 2. Investments and Fair Value Measurements

ASC Topic 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quote prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to measurements involving significant unobservable inputs (Level 3).

The three levels of the fair value hierarchy are as follows:

Level 1: Quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities include debt and equity securities that are traded in an active exchange market. Stocks, equity and fixed income mutual funds, and U.S. treasuries are included in the Institute's Level 1 assets.

Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs considered observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 2 assets and liabilities include debt securities with quoted market prices that are traded less frequently than exchange-traded instruments. U.S. government agency securities related to the Institute's charitable gift annuities are included in the Institute's Level 2 assets. Liabilities under charitable gift annuities and charitable remainder unitrusts are included in the Institute's Level 2 liabilities. Liabilities under charitable gift annuities are recognized for the present value of future cash flows expected to be paid to the donor.

These liabilities are adjusted during the term of the annuities for payments, accretion of discounts and changes in life expectancies. Liabilities under charitable remainder unitrusts are recognized as the difference between the fair value of the assets contributed to the trust and the present value of future cash flows expected to be received upon expiration of the trust.

These liabilities are adjusted during the term of the trusts for payments, accretion of discounts and changes in life expectancies. The Institute uses Internal Revenue Service (IRS) discount rates and mortality tables.

Note 2. Investments and Fair Value Measurements (Continued)

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. The Institute's beneficial interest in perpetual trust is included in Level 3 assets. The fair value of the Institute's beneficial interest in perpetual trust is measured using the fair value of the assets contributed to the trust as no facts and circumstances indicate that the fair value of the beneficial interest differs from the fair value of the assets contributed to the trust.

The estimated fair value for stocks, U.S. treasuries, money market funds and mutual funds is based on quoted market prices in active markets at the reporting date multiplied by the quantity on hand. U.S. government agency securities and certificate of deposits are priced based on their stated interest rates and quality ratings. The interest and quality ratings are observable at commonly quoted intervals for the full-term of the instruments.

The Institute did not have any assets or liabilities valued at fair value on a nonrecurring basis during the years ended September 30, 2022 and 2021. Cash equivalents consisting of money market accounts and overnight deposits are included as Level 1 estimates.

The common trust funds are valued using the net asset value (NAV) or its equivalent to determine the fair value of all the underlying investments. The funds are not subject to the provisions of fair value measurement because they are held at NAV as a practical expedient rather than fair value. NAVs for these funds are valued weekly and redemptions from these funds are permitted daily. There are no unfunded commitments for these investments.

The State Street Bank and Trust Company State Street S&P 500® Ex Tobacco Index Non-Lending Common Trust Fund (a socially responsible index fund that excludes stocks in tobacco products) and the State Street Bank and Trust Company Fixed Income Fund for Charitable Trusts are common trust funds used for the investment of the Institute's gift annuity (see Note 3).

The investment objective of these funds is consistent with the Investment Policy. See Note 9 for more information about the Institute's Investment Policy. The investment objective of the funds are to approximate as closely as practicable, before expenses, the performance of the S&P 500® Ex Tobacco Index over the long-term and to obtain both reasonable current income and safety of principal through investment primarily in fixed income securities, respectively.

The NAV of each fund is determined as of the last business day of each month. Issuances and redemptions of fund units may be made on such days based upon the NAV per unit of the respective fund.

Note 2. Investments and Fair Value Measurements (Continued)

The following tables present a summary of the fair value measurements of the Institute’s investments within the fair value hierarchy as of September 30, 2022 and 2021:

	2022			
	Total	Level 1	Level 2	Level 3
Financial assets:				
Investments:				
Operating fund:				
Equity mutual funds	$ 1,304,348	$ 1,304,348	$ -	$ -
Certificates of deposit	891	891	-	-
Total operating fund investments	1,305,239	1,305,239	-	-
Cancer research fund (Notes 7 and 8):				
Fixed income mutual funds	788,868	788,868	-	-
Equity mutual funds	882,752	882,752	-	-
Common stock	488,738	488,738	-	-
Total cancer research fund investments	2,160,358	2,160,358	-	-
Charitable gift annuities (Note 3):				
U.S. treasuries	308,345	308,345	-	-
U.S. government agency securities	74,353		74,353	-
Total charitable gift annuity investments	382,698	308,345	74,353	-
Charitable remainder unitrusts (Note 3):				
Equity mutual funds	583,785	583,785	-	-
Fixed income mutual funds	236,861	236,861	-	-
Total charitable remainder unitrusts investments	820,646	820,646	-	-
Total investments	4,668,941	4,594,588	74,353	-
Beneficial interest in perpetual trust (Note 3)	308,626	-	-	308,626
Total financial assets	$ 4,977,567	$ 4,594,588	$ 74,353	$ 308,626
Financial liabilities (Note 3):				
Liabilities under charitable gift annuities	$ 851,051	$ -	$ 851,051	$ -
Liabilities under charitable remainder unitrusts	354,387	-	354,387	-
Total financial liabilities	$ 1,205,438	$ -	$ 1,205,438	$ -

Note 2. Investments and Fair Value Measurements (Continued)

	2021			
	Total	Level 1	Level 2	Level 3
Financial assets:				
Investments:				
Operating fund:				
Equity mutual funds	$ 1,567,891	$ 1,567,891	$ -	$ -
Certificates of deposit	50,000	-	50,000	-
Total operating fund investments	1,617,891	1,567,891	50,000	-
Cancer research fund (Notes 7 and 8):				
Fixed income mutual funds	871,416	871,416	-	-
Equity mutual funds	1,071,337	1,071,337	-	-
Common stock	576,470	576,470	-	-
Total cancer research fund investments	2,519,223	2,519,223	-	-
Charitable gift annuities (Note 3):				
U.S. treasuries	335,332	335,332	-	-
U.S. government agency securities	77,824	-	77,824	-
Total charitable gift annuity investments	413,156	335,332	77,824	-
Charitable remainder unitrusts (Note 3):				
Equity mutual funds	802,706	802,706	-	-
Fixed income mutual funds	308,646	308,646	-	-
Total charitable remainder unitrusts investments	1,111,352	1,111,352	-	-
Total investments	5,661,622	5,533,798	127,824	-
Beneficial interest in perpetual trust (Note 3)	404,897	-	-	404,897
Total financial assets	$ 6,066,519	$ 5,533,798	$ 127,824	$ 404,897
Financial liabilities (Note 3):				
Liabilities under charitable gift annuities	$ 986,920	$ -	$ 986,920	$ -
Liabilities under charitable remainder unitrusts	505,346	-	505,346	-
Total financial liabilities	$ 1,492,266	$ -	$ 1,492,266	$ -

Note 2. Investments and Fair Value Measurements (Continued)

The table below reconciles total investments to the statements of financial position at September 30, 2022 and 2021:

	2022	2021
Investments held at fair value	$ 4,668,941	$ 5,661,622
Investments held at NAV, below	2,159,126	2,466,614
	$ 6,828,067	$ 8,128,236

Investments held using NAV as a practical expedient:

	2022	2021
Common trust funds (closed fund)	$ 2,159,126	$ 2,466,614
	$ 2,159,126	$ 2,466,614

Note 3. Split-Interest Agreements

The Institute is the beneficiary of various split-interest agreements, including charitable gift annuities (for which a financial institution acts as trustee), charitable remainder unitrusts (for which the Institute acts as the trustee) and a perpetual trust (for which a financial institution acts as the trustee).

Under charitable gift annuity agreements, the Institute pays a fixed annuity amount for the life of the beneficiary, and receives the remaining assets upon the beneficiary's death, as set forth in the annuity agreements. Under charitable remainder unitrust agreements, the donor establishes and funds a trust. As trustee, the Institute makes specified distributions to designated beneficiaries over the trust term. Upon termination of the trust, the Institute receives all or a portion of the remaining trust assets, as set forth in the trust agreement. Under the perpetual trust, the assets are held by a trustee and the Institute receives specified income in perpetuity.

The assets held in charitable remainder unitrusts, charitable gift annuities and perpetual trusts are stated at fair value. Recorded liabilities to beneficiaries represent the present value of the estimated future payments based on actuarial assumptions using the 2012 IAR Mortality Table. Liabilities are updated annually based on changes in life expectancies and discount rates and the changes in value are reported as change in value of split-interest agreement liability in the statements of activities. At September 30, 2022 and 2021, the discount rates used to value liabilities under charitable gift annuities and charitable remainder unitrusts was 3.6% and 1%, respectively.

Contribution revenue is recognized based on the net amount of the assets and liabilities of split-interest agreements received in a given period, and the changes in the values of agreements received in prior years. Contribution revenue was $92,240 and $166,771 for the years ended September 30, 2022 and 2021, respectively. Distributions were $95,346.34 and $97,248 for the years ended September 30, 2022 and 2021, respectively.

In accordance with New Jersey state regulations for gift annuities, the Institute maintains segregated assets of $100,000 related to specific gifts, included in investments at September 30, 2022 and 2021.

Note 3. Split-Interest Agreements (Continued)

The balances related to the Institute's split-interest agreements at September 30, 2022 and 2021, were:

	2022	2021
Charitable gift annuities:		
Cash and cash equivalents	$ 104,311	$ 52,527
Investments:		
U.S. treasuries	308,345	335,332
U.S. government agency securities	74,353	77,824
Common trust funds	2,159,126	2,466,614
Total charitable gift annuities	$ 2,646,135	$ 2,932,297
Liabilities under charitable gift annuities	$ 851,051	$ 986,920
Charitable remainder unitrusts:		
Cash and cash equivalents	$ 4,893	$ 6,716
Investments:		
Equity mutual funds	583,785	802,706
Fixed income mutual funds	236,861	308,646
Total charitable remainder unitrusts	$ 825,539	$ 1,118,068
Liabilities under charitable remainder unitrusts	$ 354,387	$ 505,346

	2022	2021
Perpetual trust:		
Beneficial interest in perpetual trust	$ 308,626	$ 404,897
Net (loss) gain on beneficial interest in perpetual trust	$ (96,271)	$ 35,849

Note 4. Bequests Receivable, Net

Bequests receivable, net consists of the following as of September 30, 2022 and 2021:

	2022	2021
Unconditional bequests expected to be collected:		
One year or less	$ 1,860,511	$ 1,636,079
	1,860,511	1,636,079
Allowance for uncollectable bequests	-	-
	$ 1,860,511	$ 1,636,079

Note 5. Property and Equipment, Net

Property and equipment, net consists of the following as of September 30, 2022 and 2021:

	2022	2021
Donated land	$ 5,900	$ 5,900
Furniture and fixtures	246,158	246,158
Equipment	357,759	363,652
Leasehold improvements	513,031	513,031
	1,122,848	1,128,741
Less accumulated depreciation and amortization	811,938	700,452
	$ 310,910	$ 428,289

Note 6. Grants Payable

The Institute awards grants for cancer research to various scientific projects and research facilities. Grants are awarded by the Board of Directors upon the recommendation of a Grant Review Panel, which is separate from the Board. The responsibility of the Grant Review Panel is to review grant requests and consult with the Board of Directors during the grant approval process. The Grant Review Panel is subject to a conflict of interest policy under which a member is disqualified from evaluating any grant proposal submitted by an organization or institution with which the particular member is affiliated.

Grants payable at September 30, 2022, are scheduled to be funded in future fiscal years as follows:

2023	$ 1,127,384
2024	742,490
2025	268,125
2026	41,250
	$ 2,179,249

Note 7. Board Designated Net Assets

The Board has designated certain funds of net assets without donor restrictions to be part of the Institute’s Cancer Research Fund. Annual distributions from the Cancer Research Fund, which are approximately 10% of its cumulative balance, support grants awarded by the Institute.

Note 8. Net Assets With Donor Restrictions

Net assets with donor restrictions were composed of the following at September 30, 2022 and 202:

	2022	2021
Purpose restrictions:		
Gould Trust	$ 1,980,000	$ -
Cancer Research Fund (endowment earnings)	1,041,775	1,329,461
Time restrictions:		
Held under split-interest agreements	571,151	712,725
Bequests receivable	1,860,511	1,636,079
Permanent restrictions:		
Beneficial interest in perpetual trust	308,626	404,897
Endowments (perpetual portion)	698,277	698,277
	$ 6,460,340	$ 4,781,439

Net assets related to split-interest agreements are reported as net assets with donor restrictions until the gift matures. Bequests recognized as revenue that will be collected in future periods are reported as net assets with donor restrictions until the period they are collected.

Note 9. Endowment Net Assets

The Institute adopted the provisions of FASB ASC 958-205-50-1A, Reporting Endowment Funds. These provisions provide guidance on the net asset classification of donor-restricted endowment funds for a nonprofit organization that is subject to an enacted version of the Uniform Prudent Management of Institutional Funds Act of 2006 (the Act) and also require disclosures about endowment funds, both donor-restricted endowment funds and board-designated endowment funds.

The Institute's endowments are pooled with 24 individual funds established for a variety of purposes. Its endowment includes donor-restricted endowment funds, donor-restricted funds and funds designated by the Board of Directors to function as endowments. As required by U.S. GAAP, net assets associated with endowment funds, including funds designated by the Board of Directors to function as endowments, are classified and reported based on the existence or absence of donor-imposed restrictions.

The Board of Directors of the Institute has interpreted the Act as requiring the preservation of the fair market value of the original gift as of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. As a result of this interpretation, the Institute classifies as permanently restricted net assets (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment and (c) accumulations to the permanent endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund. The remaining portion of the donor-restricted endowment fund that is not classified in permanently restricted net assets is classified as net assets with donor restrictions until those amounts are appropriated for expenditure by the organization in a manner consistent with the standard of prudence prescribed by the Act. In accordance with the Act, the Institute considers the following factors in making a determination to appropriate or accumulate donor-restricted endowment funds: (1) the duration and preservation of the fund, (2) the purposes of the Institute and the donor-restricted endowment fund, (3) general economic conditions, (4) the possible effect of inflation and deflation, (5) the expected total return from income and the appreciation of investments, (6) other resources of the Institute and (7) the investment policies of the organization.

Note 9. Endowment Net Assets (Continued)

The Institute's Investment Policy contains a section on donor-restricted funds, which includes the following: the classification of restricted gifts, the investment of restricted gifts, the definition of income earned and the calculation of annual distributions. The classifications of restricted gifts are outlined in Note 2. Gifts are pooled and invested to ensure assets increase over time thereby enhancing the funds' long-term health and fiscal viability. The Institute relies on a total return strategy in which investment returns are achieved through both capital appreciation and current yield. The Institute targets a diversified asset allocation that utilizes fixed income and equity-based investments to achieve its long-term objectives within prudent risk constraints. Income earned includes interest, dividends and realized/unrealized gains and losses unless otherwise specified by the donor. Distributions are made annually at a rate not to exceed 5% of the average fair market value of the permanently restricted funds, calculated on the basis of market values determined annually and averaged over a period of three years immediately preceding the year for which the distribution is to be made. Annual distributions are also made at a rate not to exceed 10% of the fair market value of the net assets with donor restrictions and board-designated funds. The most recent Investment Policy was reviewed and approved by the Board of Directors in April 2018.

Endowment net assets composition by type of fund as of September 30, 2022:

	Without Donor Restrictions	With Donor Restrictions	Total
Donor-restricted endowment funds	$ -	$ 1,740,052	$ 1,740,052
Board-designated endowment funds	344,836	-	344,836
	$ 344,836	$ 1,740,052	$ 2,084,888

Changes in endowment net assets for the fiscal year ended September 30, 2022:

	Without Donor Restrictions	With Donor Restrictions	Total
Endowment net assets, beginning of year	$ 477,053	$ 2,027,738	$ 2,504,791
Investment return:			
Investment income	9,091	41,627	50,718
Net losses (realized and unrealized)	(103,004)	(485,136)	(588,140)
Total investment return	(93,913)	(443,509)	(537,422)
Contributions	-	290,307	290,307
Appropriation of endowment assets for expenditure	(38,304)	(134,484)	(172,788)
Endowment net assets, end of year	$ 344,836	$ 1,740,052	$ 2,084,888

Note 9. Endowment Net Assets (Continued)

Endowment net assets composition by type of fund as of September 30, 2021:

	Without Donor Restrictions	With Donor Restrictions	Total
Donor-restricted endowment funds	$ -	$ 2,027,738	$ 2,027,738
Board-designated endowment funds	477,053	-	477,053
	$ 477,053	$ 2,027,738	$ 2,504,791

Changes in endowment net assets for the fiscal year ended September 30, 2021:

	Without Donor Restrictions	With Donor Restrictions	Total
Endowment net assets, beginning of year	$ 449,280	$ 1,595,725	$ 2,045,005
Investment return:			
Investment income	14,850	52,670	67,520
Net gains (realized and unrealized)	65,929	234,418	300,347
Total investment return	80,779	287,088	367,867
Contributions	-	297,100	297,100
Appropriation of endowment assets for expenditure	(53,006)	(152,175)	(205,181)
Endowment net assets, end of year	$ 477,053	$ 2,027,738	$ 2,504,791

Funds in deficiencies: From time to time, the fair value of assets associated with individual donor-restricted endowment funds may fall below the original value of the gift donated to the permanent endowment. Deficiencies of this nature are reported as net assets without donor restrictions. At September 30, 2022 and 2021, the Institute had deficiencies of $61,586 and $0, respectively.

Note 10. Income Taxes

The Institute is recognized as exempt from federal income tax under Section 501(c)(3) of the Internal Revenue Code (IRC) on income other than unrelated business income. No provision for income taxes is required as of September 30, 2022 and 2021, since the Institute had no unrelated business income. The Institute has been recognized by the IRS as a publicly supported organization and is therefore not a private foundation. Management annually reviews its tax position and has determined that there are no uncertain tax positions that require recognition in the financial statements.

Note 11. Employee Benefits

Defined contribution plan: The Institute sponsors a defined contribution retirement plan for those employees who have completed one year of service with the Institute. Employees vest in the retirement plan at a rate of 20% a year until fully vested. Employees become fully vested at age 59½ regardless of start date. The minimum number of hours required for eligibility is 1,000 hours worked in a plan year. The age of eligibility for participation in the plan is age 18. Employees may borrow a percentage of their vested account balance. Retirement plan contributions for the years ended September 30, 2022 and 2021, were approximately $0 and $81,000, respectively.

Note 11. Employee Benefits (Continued)

Defined contribution 403(b) plan: The Institute also provides a defined contribution 403(b) retirement plan to all employees. Participants may elect to contribute a portion of their pretax compensation to the plan. Annual contributions may not exceed the limits prescribed by IRC Section 402(g). Employees are eligible for this plan upon employment and immediately have a fully vested interest in their contributions. The Institute does not make contributions to this plan.

Employment agreements: To retain the services of a key employee, the Institute entered into an employment agreement in 2011. This agreement provides for annual compensation and other compensation, such as bonuses, supplemental retirement and other benefits. The employee retired and the Institute made a lump-sum payment during the year ended September 30, 2021.

In accordance with ASC Topic 715, Employers' Accounting for Defined Benefit Pension and Other Postretirement Plans, the gains or losses and prior service costs that arise during the period but are not recognized as components of net periodic benefit costs are recognized separately on the statements of activities as pension related changes other than net periodic benefit costs.

The components of accrued benefit costs and net periodic benefit costs for other postretirement benefits as of September 30, 2022 and 2021, are as follows:

	2022	2021
Change in benefit obligation:		
Benefit obligation at beginning of year	$ -	$ 1,365,728
Service cost	-	13,609
Interest cost	-	8,122
Actuarial loss	-	10,696
Benefits paid	-	(1,398,155)
Benefit obligation at end of year	-	-
Funded status at end of year	-	-
Accrued benefit cost	$ -	$ -

The funded status is included in accrued benefit cost in the accompanying statements of financial position. The Institute uses an annual measurement date of September 30 to determine benefit obligations for the plan.

For the year ended September 30, 2021, the benefit obligation was calculated using a discount rate of 2.4%. For the year ended September 30, 2021, the net periodic benefit cost was calculated using a discount rate of 2.40%. The rate of future compensation increases is estimated at 3% for the year ended September 30, 2021.

	2022	2021
Net periodic benefit cost:		
Service cost	$ -	$ 13,609
Interest cost	-	8,122
Amortization of net loss	-	222,597
One-time recognition of outstanding net loss	-	147,269
Net periodic benefit cost	$ -	$ 391,597

Note 11. Employee Benefits (Continued)

	2022	2021
Pension related changes other than net periodic benefit cost consist of:		
Net loss	$ -	$ (10,696)
Amortization of net loss	-	222,597
One-time recognition of outstanding net loss	-	147,269
	$ -	$ 359,170

Note 12. Related Parties

Fundraising and professional services: Direct Response Consulting Services (DRCS) provides fundraising and other professional services to the Institute. The Institute's management performs a periodic review of amounts paid for fundraising services and believes that the payments are comparable to or less than payments that would be made to unrelated parties for such services. DRCS is owned by one of the founders of the Institute who is not currently a Board Members. Under the Institute's governing legal instruments, the above individual may not vote to elect or remove members of the Board of Directors while under a service contract with the Institute and for a period of three years thereafter.

For the years ended September 30, 2022 and 2021, the Institute incurred expenses of approximately $452,000 and $417,000, respectively, for fundraising and other professional services, for which payment was made to DRCS and DRCS' related companies. As of September 30, 2022 and 2021, the Institute owed an outstanding payable balance to DRCS and DRCS' related companies of $0 and $2,403, respectively.

Affiliated charities: The Institute operates jointly with affiliates in the United Kingdom, through the World Cancer Research Fund (WCRF United Kingdom—founded 1990); in the Netherlands, through the Stichting Wereld Kanker Onderzoek Fonds (WCRF NL) (WCRF Netherlands—founded 1994) and in Hong Kong, through the World Cancer Research Fund Limited (WCRF Hong Kong—founded 1997). These organizations promote, fund, support and encourage research and public education as to the causes and treatment of cancer for the general benefit of the public.

In 2000, the Institute entered into a written membership agreement with the World Cancer Research Fund International (WCRF International). As part of this membership agreement, the Institute will pay membership dues in return for services being provided by WCRF International. WCRF International is an umbrella association comprised of AICR and the WCRF entities. In 2022 and 2021, the Institute paid dues of $69,219 and $65,940 to WCRF International (USD equivalent of £50,000), respectively.

WCRF International also signed membership agreements with WCRF United Kingdom, WCRF Netherlands and WCRF Hong Kong. These entities are each affiliated charities of the Institute but are not consolidated by the Institute under U.S. GAAP.

WCRF International is funded by contributions from the Institute and its affiliates. In 2022 and 2021, the Institute paid contributions totaling $256,143 and $296,578, respectively, to WCRF International. The Institute also provided services to WCRF International and recognized related affiliate service fees of $899,280 and $1,030,788 in 2022 and 2021, respectively. The cost of services incurred by the Institute and billed to WCRF International are allocated among research, public health education, management and general and fundraising based upon the service provided.

Note 12. Related Parties (Continued)

When necessary, the Institute will make payments to U.S. vendors on behalf of WCRF affiliates who purchase goods or services in the U.S. The Institute is reimbursed by the respective affiliate for the payment and does not report revenue or expense associated with these transactions.

The affiliate transactions described above are recorded in due from affiliates and due to affiliates in the statements of financial position. The summary activity in these accounts for the years ended September 30, 2022 and 2021, is as follows:

	2022				
	WCRF International	WCRF United Kingdom	WCRF Netherlands	WCRF Hong Kong	Totals
Beginning balance	$ 416,678	$ (258,848)	$ -	$ 37,210	$ 195,040
Reimbursed expenses	79,333	(83,223)	-	-	(3,890)
Dues	(69,219)	-	-	-	(69,219)
Contributions	(256,143)		-	-	(256,143)
Service fee	899,280	660,000	-	-	1,559,280
Payments received	(752,313)	264,645	-	-	(487,668)
Ending balance	$ 317,616	$ 582,574	$ -	$ 37,210	$ 937,400

	2021				
	WCRF International	WCRF United Kingdom	WCRF Netherlands	WCRF Hong Kong	Totals
Beginning balance	$ 606,513	$ (806,788)	$ 1,795	$ 37,210	$ (161,270)
Reimbursed expenses	97,281	(118,060)	-	-	(20,779)
Dues	(65,940)	-	-	-	(65,940)
Contributions	1,030,788	(200,000)	-	-	830,788
Service fee	(296,578)	-	-	-	(296,578)
Payments received	(955,386)	866,000	(1,795)	-	(91,181)
Ending balance	$ 416,678	$ (258,848)	$ -	$ 37,210	$ 195,040

Note 13. Allocation of Joint Costs

The Institute incurred joint costs of $5,091,503 and $4,728,331 in 2022 and 2021, respectively, for informational materials used for direct mail, telemarketing and other campaigns that included fundraising appeals. In fiscal year 2022, $1,985,325 was allocated to fundraising, $3,105,934 was allocated to education and $244 was allocated to management and general expense. In fiscal year 2021, $1,787,126 was allocated to fundraising, $2,930,633 was allocated to education and $10,572 was allocated to management and general expense.

Note 14. Lease Commitments

In December 2016, the Institute entered into a new operating lease agreement for its headquarters to be located in Arlington, Virginia, with a commencement date of August 2017. The Institute will lease the building and related improvements under an 11-year and 2-month lease agreement with an option to cancel the lease with one year's notice any time after September 2023. The rental cost of the headquarters includes a base rental, real estate and personal property taxes and other operating costs associated with the building. The lease agreement includes provisions for fixed rent escalations and building operating costs.

Rent expense was approximately $300,000 for both 2022 and 2021.

Future minimum payments under the noncancelable portion of the operating lease at September 30, 2022, for years ending September 30 are as follows:

Years ended September 30:	
2023	$ 421,468
2024	433,048
2025	444,921
2026	457,188
2027	469,748
Thereafter	502,814
	$ 2,729,187

Note 15. Liquidity and Availability of Financial Assets

The Institute regularly monitors liquidity to meet its annual operating needs and other contractual commitments while also striving to maximize the return on investment of its funds not required for annual operations. Financial assets available for general expenditure, that is, without donor or other restrictions limiting their use, within one year of the balance sheet date, comprise the following at September 30, 2022 and 2021:

	2022	2021
Cash and cash equivalents	$ 5,958,891	$ 6,418,874
Accounts receivable, net	97,957	126,128
Due from affiliates	937,400	453,888
Bequests receivable	1,860,511	1,636,079
Investments	6,828,067	8,128,236
Beneficial interest in perpetual trust	308,626	404,897
	15,991,452	17,168,102
Less those unavailable for general expenditure within one year due to:		
Board-designated endowment funds	(344,836)	(477,053)
Donor imposed restrictions	(6,460,340)	(4,781,439)
Financial assets available to meet cash needs for general expenditure within one year	$ 9,186,276	$ 11,909,610